Vera continuing plans to rapidly advance atacicept into a pivotal Phase 3 trial in 1H 2023; full data to be presented at upcoming medical congresses
Company plans to prioritize and focus current resources on the advancement of atacicept in IgA Nephropathy into a pivotal Phase 3 trial, extending cash runway to Q4 2024
Conference call and webcast to take place on January 30th at 8:00am ET
Vera will host a conference call and webcast with slide presentation at 8:00 a.m. ET on January 30, 2023. The live webcast will be available here, and on the Events & Presentations page of the Vera website, with the recording and presentation available immediately following the event.
https://finance.yahoo.com/news/vera-therapeutics-releases-36-week-110000414.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.